Block Listing Review and Total Voting Rights

RNS Number : 5776Q

ReNeuron Group plc

01 March 2021

 

ReNeuron Group plc

("ReNeuron" or the "Company")

Block Listing Review and Total Voting Rights

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements.

Name:	ReNeuron Group plc
Name of Scheme:	ReNeuron Share Option Schemes
Period of Return:	From 1 September 2020 to 28 February 2021
Balance of unallotted securities under scheme(s) from previous return:	674,687 Ordinary Shares (of 1p each)
Plus: The amount by which the block scheme(s) has been increased since the date of the last Review (if any increase has been applied for):	N/A
Less: Number of securities issued/allotted under scheme(s) during period	11,000
Equals: Balance under scheme(s) not yet issued/allotted at end of period:	663,687 Ordinary Shares
Number and class of securities originally admitted and the date of admission:	20,000 ordinary shares on 13 May 2010

Total Voting Rights

At 28 February 2021, the Company had 56,855,705 Ordinary Shares in issue, each carrying one voting right.

As the Company holds no ordinary shares in treasury, the figure of 56,855,705 may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Contacts:

ReNeuron		www.reneuron.com/investors
Olav Hellebø, Chief Executive Officer		Via Walbrook PR
Michael Hunt, Chief Financial Officer
Stifel Nicolaus Europe Limited (NOMAD and Joint Broker) Ben Maddison, Stewart Wallace		[phone]
Allenby Capital Limited (Joint Broker)		[phone]
James Reeve/George Payne (Corporate Finance)
Tim Sohal (Sales & Corporate Broking)
Walbrook PR (Media & Investor Relations)	[phone] or [e-mail]
Paul McManus, Alice Woodings		[phone] / [phone]

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa. 

ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain.  he Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  For further information visit www.reneuron.com

 

END

 

 

MSCDKABQABKDNBB